27 completed, 4 unknown, 3 recruiting, 2 terminated. 36 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 36 | Completed 27, Unknown 4, Recruiting 3, Terminated 2 |
| Phase 2 | 7 | Completed 4, Recruiting 1, Terminated 1, Unknown 1 |
Follow Plaque Psoriasis: new trials by email Literature Review of Plaque Psoriasis trials Research Report on Plaque Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period ZP9830, Placebo - Plaque Psoriasis | Phase 1 | Recruiting | Zealand Pharma | 32 | 2026-07-22 | 2026-07-29 |
| A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis. Tapinarof Cream, 1%, Vtama® (Tapinarof) Cream, 1%, Placebo Control - Plaque Psoriasis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 575 | 2025-10-13 | 2026-04-22 |
| A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis CS32582 capsule（low dose） or matched placebo, CS32582 capsule（high dose） or matched placebo, CS32582 capsule（low dose） - Plaque Psoriasis | Phase 1 / Phase 2 | Recruiting | Chipscreen Biosciences, Ltd. | 220 | 2025-09-08 | 2026-11-05 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis ASC50 tablets or matching placebo - Plaque Psoriasis | Phase 1 | Completed | Ascletis Pharma (China) Co., Limited | 55 | 2025-06-04 | 2026-09-30 |
| A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis UA026, Placebo - Plaque Psoriasis, Healthy Volunteer | Phase 1 | Recruiting | Usynova Pharmaceuticals Ltd. | 124 | 2025-05-08 | 2025-11-17 |
| A Multicentre Randomized Controlled Clinical Study on the Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment Therapy for Psoriasis With Blood Stasis Syndrome. Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment, placebo - Plaque Psoriasis | Phase 1 | Unknown | Beijing Hospital of Traditional Chinese Medicine | 96 | 2024-06-01 | 2024-05-02 |
| Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis AX-158, Placebo - Psoriasis, Plaque Psoriasis | Phase 1 / Phase 2 | Completed | Artax Biopharma Inc | 31 | 2023-11-30 | 2025-10-03 |
| A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis. CAN10, CAN10 - Placebo - Healthy, Plaque Psoriasis | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 80 | 2023-08-21 | 2026-02-05 |
| Study of Efficacy and Safety of Investigational Treatment in Patients With Nail Psoriasis AT193 - Nail Psoriasis, Plaque Psoriasis | Phase 1 | Unknown | Azora Therapeutics Australia Pty Ltd | 34 | 2022-04-01 | 2023-01-25 |
| Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685 ONO-4685, Placebo - Plaque Psoriasis | Phase 1 | Completed | Ono Pharmaceutical Co., Ltd. | 33 | 2022-03-25 | 2024-08-21 |
| A Study of DLX105-DMP in Subjects With Plaque Psoriasis DLX105-DMP - Plaque Psoriasis | Phase 1 | Completed | DelArrivo, Inc. | 10 | 2022-03-21 | 2023-05-03 |
| A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis DC-806, Placebo - Plaque Psoriasis | Phase 1 | Completed | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 104 | 2021-09-22 | 2025-02-05 |
| A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis HB0017 150mg or matching placebo, HB0017 300mg or matching placebo, HB0017 450mg or matching placebo - Plaque Psoriasis | Phase 1 | Completed | Huabo Biopharm Co., Ltd. | 30 | 2021-09-02 | 2022-07-07 |
| A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis GLPG3667, Placebo - Plaque Psoriasis | Phase 1 | Completed | Lakefront Biotherapeutics NV | 30 | 2020-10-19 | 2021-05-27 |
| A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol) Pharmacokinetics of certolizumab pegol - Rheumatoid Arthritis, Psoriatic Arthritis | Phase 1 | Completed | UCB Biopharma SRL | 22 | 2020-06-19 | 2024-09-19 |
| Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis ARQ-151- cream 0.3% - Plaque Psoriasis | Phase 1 | Completed | Arcutis Biotherapeutics, Inc. | 26 | 2020-03-10 | 2022-08-03 |
| Autologous Natural Killer Cells in Subjects With Plaque Psoriasis Study Product: SNK01 - Plaque Psoriasis | Phase 1 | Completed | NKGen Biotech, Inc. | 9 | 2019-07-18 | 2020-06-26 |
| Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS 40 mg MSB11022 - Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis | Phase 1 | Completed | Fresenius Kabi SwissBioSim GmbH | 216 | 2019-07-15 | 2020-03-25 |
| An Open-Label Study to Assess Safety Topical TA-102 A, Topical TA-102 B, Topical TA-102 C - Plaque Psoriasis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 88 | 2018-04-04 | 2022-12-02 |
| A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis AK101, placebo - Plaque Psoriasis | Phase 1 / Phase 2 | Completed | Akeso | 96 | 2018-01-09 | 2025-03-03 |
Showing 20 of 36. Sign in to see all of them.
Psoriasis (8) · Arthritis, Psoriatic (2) · Arthritis, Rheumatoid (2) · Crohn Disease (2) · Arthritis, Juvenile (1) · Axial Spondyloarthritis (1) · Colitis, Ulcerative (1) · Hidradenitis Suppurativa (1) · Plaque, Amyloid (1) · Skin Diseases (1) · Spondylitis, Ankylosing (1)
Skin Diseases, Papulosquamous (10) · Skin and Connective Tissue Diseases (10) · Skin Diseases (9) · Ankylosis (2) · Arthritis (2) · Autoimmune Diseases (2) · Bone Diseases (2) · Connective Tissue Diseases (2) · Digestive System Diseases (2) · Gastroenteritis (2) · Gastrointestinal Diseases (2) · Immune System Diseases (2) · Inflammatory Bowel Diseases (2) · Intestinal Diseases (2) · Joint Diseases (2)
Suspensions (2) · Loratadine (1) · MK 0873 (1) · PF-06700841 (1) · Shk-186 peptide (1) · calcipotriene (1) · efalizumab (1) · ropsacitinib (1) · secukinumab (1) · tapinarof (1) · timolumab (1)
Pfizer (3) · Merck Sharp & Dohme LLC (2) · Sun Pharmaceutical Industries, Inc. (2) · Akeso (1) · Akros Pharma Inc. (1) · Arcutis Biotherapeutics, Inc. (1) · Artax Biopharma Inc (1) · Ascletis Pharma (China) Co., Limited (1) · Azora Therapeutics Australia Pty Ltd (1) · Beijing Hospital of Traditional Chinese Medicine (1) · Biotie Therapies Corp. (1) · Chipscreen Biosciences, Ltd. (1) · Covagen (1) · DFB Soria, LLC (1) · DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (1)
United States (15) · China (4) · Germany (4) · Canada (3) · United Kingdom (3) · Netherlands (2) · Switzerland (2) · Australia (1) · Bulgaria (1) · France (1) · Mexico (1) · Moldova (1) · Poland (1) · Romania (1) · Slovakia (1)
Natalie Yantovskiy (2) · Congjun Jiang, Master (1) · David Berk, MD (1) · Helen Timmis, MD (1) · Hongzhong Jin, MD (1) · Kristian Reich, Prof. Dr. med (1) · Manuela Casjens, MD (1) · Michael Holick, PhD, MD (1) · Project Leader (1)
PMID 20926833, PMID 26390837, PMID 29266308, PMID 31972249, PMID 35262901, PMID 36045513, PMID 36422852, PMID 37669307, PMID 38279383, PMID 38563353, PMID 40560938, PMID 42012633
2023 (1)